BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 32612954)

  • 1. Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma.
    Zilenaite D; Rasmusson A; Augulis R; Besusparis J; Laurinaviciene A; Plancoulaine B; Ostapenko V; Laurinavicius A
    Front Oncol; 2020; 10():950. PubMed ID: 32612954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral heterogeneity of Ki67 proliferation index outperforms conventional immunohistochemistry prognostic factors in estrogen receptor-positive HER2-negative breast cancer.
    Zilenaite-Petrulaitiene D; Rasmusson A; Besusparis J; Valkiuniene RB; Augulis R; Laurinaviciene A; Plancoulaine B; Petkevicius L; Laurinavicius A
    Virchows Arch; 2024 Jan; ():. PubMed ID: 38217716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral Heterogeneity and Immune Response Indicators to Predict Overall Survival in a Retrospective Study of HER2-Borderline (IHC 2+) Breast Cancer Patients.
    Radziuviene G; Rasmusson A; Augulis R; Grineviciute RB; Zilenaite D; Laurinaviciene A; Ostapenko V; Laurinavicius A
    Front Oncol; 2021; 11():774088. PubMed ID: 34858854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bimodality of intratumor Ki67 expression is an independent prognostic factor of overall survival in patients with invasive breast carcinoma.
    Laurinavicius A; Plancoulaine B; Rasmusson A; Besusparis J; Augulis R; Meskauskas R; Herlin P; Laurinaviciene A; Abdelhadi Muftah AA; Miligy I; Aleskandarany M; Rakha EA; Green AR; Ellis IO
    Virchows Arch; 2016 Apr; 468(4):493-502. PubMed ID: 26818835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma.
    Laurinavicius A; Green AR; Laurinaviciene A; Smailyte G; Ostapenko V; Meskauskas R; Ellis IO
    Oncotarget; 2015 Dec; 6(38):41134-45. PubMed ID: 26512778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data.
    Laurinavicius A; Laurinaviciene A; Ostapenko V; Dasevicius D; Jarmalaite S; Lazutka J
    Diagn Pathol; 2012 Mar; 7():27. PubMed ID: 22424533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer.
    Besusparis J; Plancoulaine B; Rasmusson A; Augulis R; Green AR; Ellis IO; Laurinaviciene A; Herlin P; Laurinavicius A
    Diagn Pathol; 2016 Aug; 11(1):82. PubMed ID: 27576949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification.
    Allott EH; Geradts J; Sun X; Cohen SM; Zirpoli GR; Khoury T; Bshara W; Chen M; Sherman ME; Palmer JR; Ambrosone CB; Olshan AF; Troester MA
    Breast Cancer Res; 2016 Jun; 18(1):68. PubMed ID: 27349894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic comparison of the proliferation markers (mitotic activity index, phosphohistone H3, Ki67), steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T₁₋₂N₀M₀ breast cancer.
    Gudlaugsson E; Klos J; Skaland I; Janssen EA; Smaaland R; Feng W; Shao Z; Malpica A; Baak JP
    Pol J Pathol; 2013 Apr; 64(1):1-8. PubMed ID: 23625593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A methodology for comprehensive breast cancer Ki67 labeling index with intra-tumor heterogeneity appraisal based on hexagonal tiling of digital image analysis data.
    Plancoulaine B; Laurinaviciene A; Herlin P; Besusparis J; Meskauskas R; Baltrusaityte I; Iqbal Y; Laurinavicius A
    Virchows Arch; 2015 Oct; ():. PubMed ID: 26481244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer global tumor biomarkers: a quality assurance study of intratumoral heterogeneity.
    Clark BZ; Onisko A; Assylbekova B; Li X; Bhargava R; Dabbs DJ
    Mod Pathol; 2019 Mar; 32(3):354-366. PubMed ID: 30327501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic role of progesterone receptor expression in a population-based analysis.
    Caldarella A; Barchielli A
    J Cancer Res Clin Oncol; 2017 Dec; 143(12):2505-2509. PubMed ID: 28889189
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
    Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer subtype discrimination using standardized 4-IHC and digital image analysis.
    Gándara-Cortes M; Vázquez-Boquete Á; Fernández-Rodríguez B; Viaño P; Ínsua D; Seoane-Seoane A; Gude F; Gallego R; Fraga M; Antúnez JR; Curiel T; Pérez-López E; García-Caballero T
    Virchows Arch; 2018 Feb; 472(2):195-203. PubMed ID: 28825136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
    Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
    BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
    Milburn M; Rosman M; Mylander C; Tafra L
    Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell-specific regulation of proliferation by Ano1/TMEM16A in breast cancer with different ER, PR, and HER2 status.
    Wu H; Wang H; Guan S; Zhang J; Chen Q; Wang X; Ma K; Zhao P; Zhao H; Yao W; Jin F; Xiao Q; Wei M
    Oncotarget; 2017 Oct; 8(49):84996-85013. PubMed ID: 29156699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma: a tissue microarray-based study.
    Nassar A; Radhakrishnan A; Cabrero IA; Cotsonis GA; Cohen C
    Appl Immunohistochem Mol Morphol; 2010 Oct; 18(5):433-41. PubMed ID: 20485156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular phenotypes of DCIS predict overall and invasive recurrence.
    Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
    Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between Ki67 and histological grade in breast cancer patients treated with preoperative chemotherapy.
    Petric M; Martinez S; Acevedo F; Oddo D; Artigas R; Camus M; Sanchez C
    Asian Pac J Cancer Prev; 2014; 15(23):10277-80. PubMed ID: 25556461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.